Aileron Therapeutics appoints Timothy Cunningham as interim CFO after Charles Garner departure

Rein Therapeutics, Inc.

Charles Garner departed as CFO on May 15, 2024; Timothy Cunningham appointed interim CFO effective May 16, 2024.
Cunningham is a consultant from Danforth Advisors, providing CFO services at an hourly rate under consulting agreement.
Cunningham, age 62, CPA, has served as CFO for Bionomics Limited and other biotech firms; no family relationships with executives.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Timothy M. Cunningham

Interim Chief Financial Officer

RNTX · Rein Therapeutics, Inc.

Effective: 2024-05-16
Filed: May 16, 2024, 7:59 PM ET

the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.

Departed

Charles Garner

Chief Financial Officer

RNTX · Rein Therapeutics, Inc.

Effective: 2024-05-15
Successor: Timothy M. Cunningham
Filed: May 16, 2024, 7:59 PM ET

Mr. Garner's departure from the Company on May 15, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy M. Cunningham was appointed as Interim Chief Financial Officer at Rein Therapeutics, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles Garner departed as Chief Financial Officer at Rein Therapeutics, Inc..

Action: departed
Role: Chief Financial Officer

Exact text from the filing

Mr. Garner's departure from the Company on May 15, 2024.

View on SEC.gov

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-140688

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.